MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
Recruiting · NCT05462236 · Registry updated 2024-07-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2024-07-09 | NCT05462236 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AUM Biosciences Pte Ltd | 1 |
| Merck Sharp & Dohme LLC | 650 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ballarat Oncology and Haematology | Wendouree | Australia | 1 |
| Cabrini Hospital | Malvern | Australia | 12 |
| Chris O'Brien Lifehouse | Camperdown | Australia | 46 |
| Pindara Private Hospital, Gold Coast Cancer Care | Benowa | Australia | 1 |
| Prince of Wales Hospital | Wollongong | Australia | 1 |